Skip to main content
Premium Trial:

Request an Annual Quote

ProteoNic, OET Expand Agreement for Use of Recombinant Protein Technology

NEW YORK (GenomeWeb News) – ProteoNic and Oxford Expression Technologies today said they have expanded a prior agreement to grant OET a license to use ProteoNic's UNic translation enhancing elements.

OET will use the technology in its flashBAC system for third-party recombinant protein production services. As part of the deal, ProteoNic, based in Leiden, The Netherlands, will provide technical support. Financial terms include upfront payments and royalty payments of an undisclosed amount.

Under the two firms' earlier collaboration, ProteoNic's UNic technology was combined with UK-based OET's flashBAC system for the enhancement of recombinant protein yields in insect cells. In addition to improving the overall efficiency and reducing costs, UNic facilitates clinical and preclinical development of biopharmaceutical products, which because of unacceptable production levels could otherwise be thrown away, the companies said.

As a result of today's deal, OET's manufacturing services will include UNic technology.

"The combination of the unique UNic technology and the flashBAC expression system has already proved itself to have a positive effect on eukaryotic protein expression," Rory Woodhouse, sales manager for OET, said in a statement. "This new agreement will enable us to build on our partnership and experience with ProteoNic, working together to provide a superior platform for our customers with more challenging to express proteins."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.